Loading...
XSHE
300463
Market cap991mUSD
Dec 05, Last price  
11.48CNY
1D
0.79%
1Q
-5.67%
Jan 2017
-53.24%
IPO
-22.24%
Name

Maccura Biotechnology Co Ltd

Chart & Performance

D1W1MN
XSHE:300463 chart
P/E
55.26
P/S
2.75
EPS
0.21
Div Yield, %
1.34%
Shrs. gr., 5y
1.89%
Rev. gr., 5y
-4.59%
Revenues
2.55b
-11.98%
521,308,317606,154,698779,426,579934,846,0801,065,169,0321,488,780,8841,969,983,7292,685,304,9463,222,956,0193,703,877,0063,980,647,1833,608,411,8952,895,769,5122,548,756,678
Net income
127m
-59.44%
120,415,498158,209,363193,155,928226,210,932251,043,594312,022,756374,132,214444,928,508525,262,640793,917,986956,604,404708,180,360312,618,556126,805,274
CFO
634m
-30.51%
85,546,596110,959,27298,392,339115,090,08433,183,26349,315,14779,033,594193,905,904459,516,3111,094,048,8101,616,683,215843,216,884912,088,535633,798,557
Dividend
Jul 03, 20240.15402 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. The company offers immunoassay products, such as chemiluminescence analyzers and reagents; clinical chemistry reagents for hepatic function, glycometabolism, iron and other, renal function, coagulation, special protein, cardiac, and lipids; and clinical laboratory products, such as automatic hematology, and automatic and semi-automatic coagulation analyzers. It also provides SARS-COV-2(COVID-19) products that includes nucleic acid detection kit and other products; glucometers; POCT products, such as fluorescence immunoassay analyzers, as well as colloidal gold kits; molecular diagnosis products, such as PCR kit; and pathology products. The company was incorporated in 1994 and is based in Chengdu, China.
URL
http://www.maccura.com/
IPO date
May 28, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT